nach oben

Erschienen in:

07.01.2019 | Original Article

Improved accuracy in DFS pattern interpretation using a novel HEp-2 ELITE system

verfasst von: Maria Infantino, O. Shovman, B. Gilburd, M. Manfredi, V. Grossi, Maurizio Benucci, A. Damiani, D. Chimenti, K. Malyavantham, Y. Shoenfeld

Erschienen in: Clinical Rheumatology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction/objectives

Accurate interpretation of DFS70 (dense fine speckled 70) and mixed antinuclear antibodies (ANAs) patterns can be challenging using conventional HEp-2 immunofluorescence (IIF) method. We evaluated a novel HEp-2 IIF substrate (HEp-2 ELITE/DFS70-KO) composed of a mixture of engineered HEp-2 devoid of the DFS70 autoantigen and conventional HEp-2 cells. The study assessed the utility of the new substrate in ANA screening and its advantages.

Method

One thousand and five consecutive routine samples sent for ANA screening were tested on both standard HEp-2 and the HEp-2 ELITE DFS70 KO substrates (ImmuGlo ANA HEp-2 and HEp-2 ELITE/DFS70-KO, Trinity Biotech, Buffalo, NY). Anti-DFS70 antibody specificity was additionally determined by immunoblot (IB). Clinical and serological data were included in the analysis of the overall impact of the novel HEp-2 substrate on DFS pattern interpretation.

Results

Of the 22 cases suspected as positive for DFS pattern alone or in combination with homogeneous or speckled patterns on conventional HEp-2 cells, 17 were interpreted with a higher accuracy using the new HEp-2 ELITE method as positive for DFS70 (monospecific DFS70 (10), mixed DFS70 (7)), speckled (3), and DFS (2) patterns.

Conclusions

The new substrate was not only useful in deciphering unclear mixed ANA patterns but also highly sensitive in detecting DFS70 pattern in comparison to the DFS70 positivity obtained using IB.

American College of Rheumatology Position Statement (2011) Methodology of testing for antinuclear antibodies. www.rheumatology.org/practice/ana_position_stmt.pdf. Approved by Board of Directors: Aug 2011

Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PL et al (2015) Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014-2015. Front Immunol 6:412CrossRefPubMedPubMedCentral

Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, Bossuyt X, Musset L, Cervera R, Plaza-Lopez A, Dias C, Sousa MJ, Radice A, Eriksson C, Hultgren O, Viander M, Khamashta M, Regenass S, Andrade LEC, Wiik A, Tincani A, Rönnelid J, Bloch DB, Fritzler MJ, Chan EKL, Garcia-de la Torre I, Konstantinov KN, Lahita R, Wilson M, Vainio O, Fabien N, Sinico RA, Meroni P, Shoenfeld Y (2014) International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 73:17–23CrossRefPubMed

Meroni PL, Schur PH (2010) ANA screening: an old test with new recommendations. Ann Rheum Dis 69:1420–1422CrossRefPubMed

Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, Tomita Y, Muro Y (2004) Anti-DFS70antibodies in 597 healthy hospital workers. Arthritis Rheum 50:892–900CrossRefPubMed

Malyavantham KS, Suresh L (2018) Simultaneous distinction of Monospecific and mixed DFS70 patterns during ANA screening with a novel HEp-2 ELITE/DFS70 knockout substrate. J Vis Exp 131

Malyavantham KL, Suresh L (2017) Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate. Auto Immun Highlights 8:3CrossRefPubMedPubMedCentral

Fritzler MJ (2011) The antinuclear antibody test: last or lasting gasp? Arthritis Rheum 63:19–22CrossRefPubMed

Basu A, Sanchez TW, Casiano CA (2015) DFS70/LEDGF p75: an enigmatic autoantigen at the interface between autoimmunity, AIDS, andcancer. Front Immunol 6:116CrossRefPubMedPubMedCentral

10.

Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM (2000) Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 105:1211–1220CrossRefPubMed

11.

Infantino M, Meacci F, Grossi V, Manfredi M, Li Gobbi F, Sarzi-Puttini P, Atzeni F, Benucci M (2017) The clinical impact of anti-DFS70 antibodies in undifferentiated connective tissue disease: case reports and a review of the literature. Immunol Res 65:293–295CrossRefPubMed

12.

Seelig CA, Bauer O, Seelig HP (2016) Autoantibodies against DFS70/LEDGF exclusion markers for systemic autoimmune rheumatic diseases (SARD). Clin Lab 62:499–517CrossRefPubMed

13.

Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE (2011) Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 63:191–200CrossRefPubMed

14.

Mahler M, Parker T, Peebles CL Andrade LE, Swart A, Carbone Y et al (2012) Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol 39:2104–2110CrossRefPubMed

15.

Bizzaro N, Tonutti E, Tampoia M, Infantino M, Cucchiaro F, Pesente F, Morozzi G, Fabris M, Villalta D (2015) Specific chemoluminescence and immunoadsorption tests for anti-DFS70 antibodies avoid false positive results by indirect immunofluorescence. Clin Chim Acta 451:271–277CrossRefPubMed

16.

Nilsson AC, Voss A, Lillevang ST (2015) DFS70 autoantibodies are rare in healthy Danish individuals but may still serve as a diagnostic aid. Scand J Immunol 82:547–548CrossRefPubMed

17.

Conrad K, Rober N, Andrade LE, Mahler M (2017) The clinical relevance ofanti-DFS70 autoantibodies. Clin Rev Allergy Immunol 52:202–216CrossRefPubMed

18.

Fritzler MJ (2016) Choosing wisely: review and commentary on anti-nuclear antibody (ANA) testing. Autoimmun Rev 15:272–280CrossRefPubMed

19.

Gundín S, Irure-Ventura J, Asensio E, Ramos D, Mahler M, Martínez-Taboada V, López-Hoyos M (2016) Measurement of anti-DFS70 antibodies in patients with ANA-associated autoimmune rheumatic diseases suspicion is cost-effective. Auto Immun Highlights 7:10CrossRefPubMedPubMedCentral

20.

Carter JB, Carter S, Saschenbrecker S, Goeckeritz BE (2018) Recognition and relevance of anti-DFS70 autoantibodies in routine antinuclear autoantibodies testing at a community hospital. Front Med (Lausanne) 5:88CrossRef

21.

Shovman O, Gilburd B, Chayat C, Amital H, Langevitz P, Watad A, Guy A, Perez D, Azoulay D, Blank M, Segal Y, Bentow C, Mahler M, Shoenfeld Y (2018) Prevalence of anti-DFS70 antibodies in patients with and without systemic autoimmune rheumatic diseases. Clin Exp Rheumatol 36:121–126PubMed

22.

Infantino M, Shovman O, Pérez D, Manfredi M, Grossi V, Benucci M et al (2018) Anti-DFS70 autoantibodies in undifferentiated connective tissue diseases subjects: what’s on the horizon? Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/key012

23.

Ogawa Y, Sugiura K, Watanabe A, Kunimatsu M, Mishima M, Tomita Y, Muro Y (2004) Autoantigenicity of DFS70 is restricted to the conformational epitope of C-terminal alpha-helical domain. J Autoimmun 23:221–231CrossRefPubMed

24.

Muro Y, Sugiura K, Morita Y, Tomita Y (2008) High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus 17:171–176CrossRefPubMed

25.

Bentow C, Fritzler MJ, Mummert E, Mahler M et al (2016) Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey. Auto Immun Highlights 7:8CrossRefPubMedPubMedCentral

26.

Bentow C, Rosenblum R, Correia P, Karayev E, Karayev D, Williams D, Kulczycka J, Fritzler MJ, Mahler M (2016) Development and multi-center evaluation of a novel immunoadsorption method for anti-DFS70 antibodies. Lupus 25:897–904CrossRefPubMed

27.

Mutlu E, Eyigör M, Mutlu D, Gültekin M (2016) Confirmation of anti-DFS70 antibodies is needed in routine clinical samples with DFS staining pattern. Cent Eur J Immunol 41:6–11CrossRefPubMedPubMedCentral

28.

Rigon A, Buzzulini F, Soda P, Onofri L, Arcarese L, Iannello G, Afeltra A (2011) Novel opportunities in automated classification of antinuclear antibodies on HEp-2 cells. Autoimmun Rev 10:647–652CrossRefPubMed

29.

Bizzaro N, Tonutti E, Villalta D (2011) Recognizing the dense fine speckled/lens epithelium-derived growth factor/p75 pattern on HEP-2 cells: not an easy task! Comment on the article by Mariz et al. Arthritis Rheum 63:4036–4037 author reply 4037–8CrossRefPubMed

30.

Mahler M, Meroni PL, Andrade LE, Khamashta M, Bizzaro N, Casiano CA, Fritzler MJ (2016) Towards a better understanding of the clinical association of anti-DFS70 autoantibodies. Autoimmun Rev 15:198–201CrossRefPubMed

31.

Bizzaro N, Pesente F, Cucchiaro F, Infantino M, Tampoia M, Villalta D, Fabris M, Tonutti E (2016) Anti-DFS70 antibodies detected by immunoblot methods: a reliable tool to confirm the dense fine speckles ANA pattern. J Immunol Methods 436:50–53CrossRefPubMed

32.

Shovman O, Gilburd B, Barzilai O, Shinar E, Larida B, Zandman-Goddard G et al (2005) Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann N Y Acad Sci 1050:380–388CrossRefPubMed

Titel: Improved accuracy in DFS pattern interpretation using a novel HEp-2 ELITE system
verfasst von: Maria Infantino
O. Shovman
B. Gilburd
M. Manfredi
V. Grossi
Maurizio Benucci
A. Damiani
D. Chimenti
K. Malyavantham
Y. Shoenfeld
Publikationsdatum: 07.01.2019
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 5/2019
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-018-04412-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Improved accuracy in DFS pattern interpretation using a novel HEp-2 ELITE system

Abstract

Introduction/objectives

Method

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Introduction/objectives

Method

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Investigation of the relationships between knee osteoarthritis and obesity via untargeted metabolomics analysis

Rebuttal letter to Dr. Fallahi’s letter about our manuscript “Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities.” Clin Rheumatol. 2018 Dec 26. https://doi.org/10.1007/s10067-018-4397-3

Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Plasma let-7i, miR-16, and miR-221 levels as candidate biomarkers for the assessment of ankylosing spondylitis in Mexican patients naïve to anti-TNF therapy

Exploring metabolic and inflammatory abnormalities in rheumatoid arthritis patients developing stroke disease: a case-control study using electronic medical record data in northern China

First trimester combined screening in patients with systemic lupus erythematosus: impact of pre-analytical variables on risk assessment

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin